-
RE-LY randomized 18,113 patients to one of its three arms. In the entire study group, dabigatran 110 mg twice per day compared with warfarin was associated with lower risks of major bleeding (2.87% vs 3.57 %), intracranial bleeding (0.23% vs 0.76%), and life-threatening bleeding (1.24% vs 1.85%).
-
In this paper, Haines and his coauthors propose a scoring system to predict risks associated with implantable cardioverterdefibrillator (ICD) implant procedures.
-
Two new drugs for treatment of hepatitis C; NSAIDs and myocardial infarction risk; AIM-HIGH clinical trial stopped; and FDA actions.
-
The authors conclude that even short-term treatment with most NSAIDs was associated with increased risk of death and recurrent MI in patients with prior MI. Neither short- nor long-term treatment with NSAIDs is advised in this population, and any NSAID use should be limited from a cardiovascular safety point of view.
-
The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) study showed that in patients with stable coronary artery disease (CAD) put on optimal medical therapy (OMT) that randomization to a percutaneous coronary intervention did not improve survival or prevent myocardial infarction.
-
-
It is believed that returning blood flow to chronically ischemic but viable myocardium in patients with heart failure due to coronary artery disease will improve symptoms and reduce mortality.
-
Hypertension is usually asymptomatic, so adherence to drug therapy is an issue, especially if the drugs used cause symptoms.
-
The province of Ontario in Canada maintains a comprehensive database of all implantable cardioverter-defibrillator (ICD) implants.
-
